Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

1.0K
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
1.0K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.1K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.1K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

18
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
18
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

994
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
994
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

671
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
671
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

282
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
282

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Management of late toxicities and specific follow-up needs of adolescent and young adult cancer survivors: recommendations from scientific societies in Spain.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2025
Same author

Overlapping in memory profiles in Spanish children with autism spectrum disorders, developmental language disorders, and attention deficit hyperactivity disorder.

Applied neuropsychology. Child·2021
Same author

Intervention in Syntactic Skills in Pupils with Developmental Language Disorder.

Psicothema·2020
Same author

Efficacy of a computer-based cognitive training program to enhance planning skills in 5 to 7-year-old normally-developing children.

Applied neuropsychology. Child·2018
Same author

EEG findings and outcomes of continuous video-EEG monitoring started prior to initiation of seizure treatment in the perinatal stroke.

Early human development·2018
Same author

[EATING DISORDERS IN PEDIATRIC AGE: A BOOM PATHOLOGY].

Nutricion hospitalaria·2015

Related Experiment Video

Updated: Feb 16, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.8K

Differential long-term medication impact on executive function and delay aversion in ADHD.

Belen Rubio Morell1, Sergio Hernández Expósito2

  • 1a Child Psychiatry Unit , Hospital Universitario de Canarias , La Laguna , Spain.

Applied Neuropsychology. Child
|December 16, 2017
PubMed
Summary

Long-term treatment with methylphenidate (MPH) or atomoxetine (ATX) improves executive functions (EF) in children with ADHD. However, neither medication demonstrated benefits for delay aversion (DAv) or risk-taking behaviors.

Keywords:
ADHDCANTABatomoxetinemethylphenidateneuropsychological assessment

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.5K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K

Related Experiment Videos

Last Updated: Feb 16, 2026

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
10:02

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

16.8K
The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

6.5K
Measuring Delay Discounting in Humans Using an Adjusting Amount Task
07:47

Measuring Delay Discounting in Humans Using an Adjusting Amount Task

Published on: January 9, 2016

16.1K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pediatrics

Background:

  • Attention-Deficit/Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention and/or hyperactivity-impulsivity.
  • Executive functions (EF) and delay aversion (DAv) are critical cognitive domains often impaired in children with ADHD.
  • Methylphenidate (MPH) and atomoxetine (ATX) are common pharmacological treatments for ADHD, but their long-term comparative effects on specific cognitive functions require further investigation.

Purpose of the Study:

  • To compare the long-term effects of MPH and ATX on executive functions (EF) and delay aversion (DAv) in children diagnosed with ADHD.
  • To evaluate the efficacy of MPH and ATX in improving specific components of EF, including verbal and spatial working memory, planning, decision-making, and inhibition.
  • To determine if MPH or ATX treatment influences delay aversion and risk-taking behaviors in pediatric ADHD patients.

Main Methods:

  • A randomized controlled trial was conducted involving children with ADHD exhibiting executive function deficits.
  • Participants were randomized to receive optimal dosages of either MPH or ATX.
  • A comprehensive neuropsychological battery assessing EF and DAv was administered at baseline (Naive), after three months (Post-1), and after six months (Post-2) of treatment. A control group also underwent assessments.
  • Parallel test forms were used to minimize practice effects.

Main Results:

  • Both MPH and ATX significantly improved scores in verbal working memory, spatial working memory, planning, decision-making, and inhibition over the treatment period.
  • Treatment response in verbal working memory was observed after three months, while improvements in spatial working memory, planning, and inhibition were noted after six months.
  • Neither MPH nor ATX demonstrated a beneficial effect on delay aversion or risk-taking behaviors in children with ADHD.

Conclusions:

  • Long-term treatment with MPH or ATX, within the range of optimal clinical dosages, effectively improves executive functions in children with ADHD.
  • The study did not find evidence that MPH or ATX treatment positively impacts delay aversion or risk-taking behaviors in this population.
  • These findings suggest that while pharmacotherapy can enhance cognitive control, specific behavioral aspects like delay aversion may require alternative or adjunctive therapeutic strategies.